Biosimilar Therapeutic Peptides Market Forecast 2026–2035
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Biosimilar Therapeutic Peptides Market Between 2026 And 2030?
The market size for biosimilar therapeutic peptides has experienced rapid expansion in recent years. This market is expected to grow from $3.5 billion in 2025 to $3.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, this growth can be attributed to factors such as the limited availability of biosimilar peptides, a reliance on innovative peptide therapies, the increasing prevalence of cancer and metabolic disorders, growing awareness of peptide-based treatments, and the development of parenteral administration methods.
The biosimilar therapeutic peptides market size is anticipated to undergo substantial growth over the coming years. It is projected to reach $6.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period will be driven by factors such as the introduction of combination and sustained-release peptides, increased manufacturing of generic peptides, the growing use of transdermal drug delivery methods, enhanced investment in peptide research and development, and increased healthcare spending on peptide-based treatments. Significant developments anticipated during this period encompass a surge in demand for biosimilar therapeutic peptides in oncology, the expansion of peptide-derived treatments for metabolic and cardiovascular conditions, greater uptake of prolonged-action and combined peptide formulations, the broadening of parenteral and transdermal administration pathways, and an emphasis on affordable generic peptides and improved access in developing economies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Biosimilar Therapeutic Peptides Market?
The widespread occurrence of chronic illnesses is anticipated to propel the biosimilar therapeutic peptide market forward. These conditions are defined as enduring health issues that necessitate continuous care and therapy, frequently persisting for extended periods or an entire lifespan. The rise in chronic ailments fuels a higher demand for economical treatment options, positioning biosimilar therapeutic peptides as an appealing choice given their reasonable cost and capacity to enhance patient accessibility and the long-term viability of healthcare systems. Furthermore, regulatory backing and robust clinical evidence contribute to expanding the market. For example, as reported in April 2025 by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, roughly 194 million U.S. adults, or 76.4%, indicated having at least one chronic condition in 2023. This prevalence stood at 59.5% for young adults, 78.4% for midlife adults, and a significant 93.0% for older adults. Consequently, the widespread occurrence of chronic diseases is projected to stimulate the expansion of the biosimilar therapeutic peptides market.
Which Market Segments Are Examined In The Biosimilar Therapeutic Peptides Market Study?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
Which Trends Are Influencing The Biosimilar Therapeutic Peptides Market?
Major companies within the biosimilar therapeutic peptide market are establishing a research platform aimed at optimizing peptide synthesis, enhancing production efficiency, and ensuring consistent quality, from the initial discovery phase through to commercialization. The Biodrug Design Accelerator, a platform designed to manage research processes for peptide drug discovery, is widely recognized as a promising frontier in the field of new drug development. For example, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, launched the Biodrug Design Accelerator platform to accelerate research in peptide drug discovery. This Biodrug Design Accelerator will assist peptide drug discovery scientists in pharmaceutical companies by speeding up and improving the efficiency of peptide drug development, particularly through the design, make, test, analyze (DMTA) cycles, ultimately enabling the accelerated and informed design of peptide drug candidates and promoting efficient communication among scientists concerning synthesis and testing.
Who Are The Primary Competitors In The Biosimilar Therapeutic Peptides Market?
Major companies operating in the biosimilar therapeutic peptides market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Novo Nordisk A/S, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd.
Read the full biosimilar therapeutic peptides market report here:
What Are The Leading Geographic Regions In The Biosimilar Therapeutic Peptides Market?
North America was the largest region in the biosimilar therapeutics peptides market in 2025. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Biosimilar Therapeutic Peptides Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3423&type=smp
Browse Through More Reports Similar to the Global Biosimilar Therapeutic Peptides Market 2026, By The Business Research Company
Biosimilar Therapeutic Peptide Market Report 2026
Pharmaceutical Drugs And Biologics Logistics Market 2026
Therapeutic Dental Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-dental-equipment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
